Generics Bulletin Explains: US Adalimumab Outlook Brightens At Mid-Point Of 2024
As PBMs Face Increasing Pressure Over Suppressing Uptake For Humira Biosimilars
The latest figures on uptake for rivals to Humira in the US show adalimumab biosimilars beginning to capture significant market share from the originator, AbbVie’s Humira, after an initially slow start in 2023.
